Navigation Links
A*STAR and Institut Merieux/bioMerieux invest S$3m ($2.2m) in tuberculosis research

An investment of S$3 million is being pumped into tuberculosis (TB) research by A*STAR's Singapore Immunology Network (SIgN), bioindustrial group Institut Mrieux and its in vitro diagnostics company bioMrieux. The project, which involves setting up a joint laboratory in Biopolis, Singapore aims to investigate and identify novel biomarkers that could allow early identification of individuals at risk of TB disease development and disease reactivation. This could lead to better diagnosis and treatment for the highly contagious disease.

At the shared lab, researchers from SIgN and bioMrieux will study the immune cells in the blood of infected individuals without active TB, and compare them with those in individuals with active TB, as well as non-infected healthy controls. Any change in gene expression and behaviour of the immune cells will then be analysed to identify biomarkers associated with TB infection and/or TB re-activation. This information would be especially pertinent to clinicians and researchers as current tests cannot reliably detect if the individual is at risk of developing the disease. In addition, the identification of predictive biomarkers will also help clinicians accurately assess patients' responses to TB treatment and deal appropriately with those who have developed drug resistance to Mycobacterium tuberculosis, the bacterium responsible for causing TB. This will lead to early and accurate assessment of the effectiveness of treatment in TB patients.

One of the lead researchers involved in the collaboration is Prof Paola Castagnoli, Scientific Director of SIgN. Said Prof Castagnoli, "The risk of developing active TB is higher in persons with weak immune systems, especially in those infected with HIV, and young children under the age of five. There is an urgent need to understand and find new ways to eradicate the disease through prediction, early detection and effective treatment and this timely collaboration seeks to accomplish exactly that." Prof Castagnoli was part of a team of scientists that published findings on the way dendritic cells and macrophages cope with Mycobacterium tuberculosis in 2008.

The co-investigator on the project, Professor Christian Brechot, who is also the Vice President of Institut Mrieux in charge of scientific and medical affairs, said, "We are very pleased with this partnership between Institut Merieux, bioMrieux and SIgN. It reflects the strategy of Institut Mrieux and its companies to establish long-term partnerships with internationally recognised research institutions, in particular in Singapore. The joint laboratory will focus its activities on tuberculosis, as part of Institut Mrieux's research programs, as well as on oncology. We look forward to the success of this important agreement."

Prof Philippe Kourilsky, Chairman of SIgN, said, "Infectious disease is an area that cannot be tackled alone Singapore has identified infectious diseases as one of its flagship areas of focus for its research efforts and is working closely with its regional and global partners; SIgN already has some meaningful partnerships with several industry players including Cytos and Vivalis. We are excited at this opportunity to partner Institut Mrieux and bioMrieux, which we hope will accelerate the process of discovery and find something of direct impact to the treatment and management of tuberculosis. This collaboration will reinforce SIgN's position as a premier immunology research centre that focuses on addressing the pressing diseases facing Singapore and the region."


Contact: Yunshi Wang
Agency for Science, Technology and Research (A*STAR), Singapore

Related medicine news :

1. A*STAR scientist receives international award for innovation in healthcare technology
2. Help wanted: Highly cited researchers needed for high-ranking positions at research institutions
3. UT Southwesterns cancer center earns National Cancer Institute designation
4. OHSU Knight Cancer Institute researchers isolate importance of gene in breast cancer prognosis
5. Kennedy Krieger Institutes Dr. Paul Lipkin selected for national health policy fellowship
6. VCU first Virginia institution to join national network of academic research centers
7. DTM Systems Is Pleased To Announce That Aaron Alsop Has Achieved The Project Management Professional Credential With The Project Management Institute
8. News from Karolinska Institutet at ESOF 2010
9. Advanced Pain Institute Opens Expanded Los Angeles Area Pain Management Center
10. Cambridge Healthtech Institute Announces its Second Annual "The Bioprocessing Summit"
11. Aspirus Heart & Vascular Institute Surgeon First in State to Implant Heart Device
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Venture Construction ... Classic Tournament held on June 20th at the Woodmont Country Club at 1201 ... Wings, an organization dedicated to helping service members that have been wounded in battle ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
Breaking Medicine Technology: